从容的小虾米
Lv41
730 积分
2024-03-28 加入
-
Population Pharmacokinetic Analysis of Guselkumab in Adults with Moderately to Severely Active Crohn’s Disease
4小时前
已关闭
-
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions
4小时前
已完结
-
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
3天前
已完结
-
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2个月前
已完结
-
Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration
2个月前
已完结
-
度洛西汀在中国健康受试者中的群体药代动力学研究
3个月前
已完结
-
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
3个月前
已完结
-
Su1788 FIRST-IN-HUMAN PHARMACOKINETIC AND SAFETY STUDY OF AN ANTITL1A ANTIBODY, TEV-48574, IN HEALTHY VOLUNTEERS AND ASTHMA PATIENTS
4个月前
已完结
-
P633 First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma Patients
4个月前
已关闭
-
Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer
5个月前
已完结